An Industry BriefingMEDTECH

Capacity.
Capability.
Promise.

The biggest talent transition of a career. Compete on capacity, not headcount.

This briefing tells you what the talent transition looks like in medtech as AI rewrites the firm-worker promise. Read it before someone else writes it for you.

GRAIL 2026 10-page briefing
Read more ↓
GRAIL industry briefing on AI in medtech for CHROs.
Get the briefing

The 10-page briefing. Worth 20 minutes.

One email. One PDF. Worth twenty minutes of your week.

Check your inbox. Your briefing is on its way.

We send it once. Work emails only.

Every CHRO at a mid-sized European medtech firm has had the same Tuesday, 7:42 a.m. Three things in the inbox. Your VP Regulatory Affairs forwarded a resignation from your senior RA reviewer. Fifteen years at the firm, the only person who has lived your last three Class IIb submissions end to end. She went to a competitor that ships in eighteen months. Your CFO attached the Mercer thriving report to the GMT calendar invite. Your CEO forwarded a note from clinical affairs: works council has opened framework-agreement consultations on three AI deployments she did not know had shipped.

You do not have a retention problem. You have a craft problem. Your firm's bench architecture is being written every week in decisions you were not invited to. The question is not whether to have one. It is whose handwriting the one you already have is in.

Your bench architecture is being written every week in decisions you were not invited to. Your senior RA director read the handwriting last month.

This is the question your CEO is already asking. The briefing below is what you want in your hand before the next GMT.

Talent Gravity. Capability Compounding. Succession Readiness.

Three questions every medtech CHRO is tracking. None of them used to be the same question. They are now.

01 · Talent Gravity

Is your senior bench staying because of you, or despite you?

Your senior RA reviewer resigned on Friday to an AI-native competitor. Your last three external senior searches each took nine to fourteen months. A single RA director departure delays a Class IIb submission twelve to eighteen months. The ones who start looking quietly have already decided.

They will not quit on the spot. They start looking quietly.
02 · Capability Compounding

Is the median regulatory associate sharper in December than in January?

The top decile is using AI daily for literature monitoring and regulatory precedent and building judgement that compounds weekly. The rest are practicing not-knowing. Your L&D budget funds RAPS certification and an annual conference. Neither moves the median.

Both groups are becoming who they practice being.
03 · Succession Readiness

Of your 2030 bench, how many came through work that still exists?

At least three of the six names came through the analyst-prep work agents have already absorbed. The external senior hire in 2030 costs a thirty to forty percent premium and brings the previous firm's submission history.

The bench architecture gets rebuilt now or gets inherited as a gap.
Inside the briefing

What you get when you download

An 11-page report for Chief Human Resources Officers at mid-market European medtech firms. Designed to be read in one sitting before your next GMT.

Inside the Briefing · Chapter 1

Your industry, your people function, and why they are one problem

The apprenticeship that built the senior reviewer compressing as agents absorb the analyst-prep layer. The senior bench under retention pressure from AI-native competitors paying 25 to 40 percent premiums. The procurement conversation shifting to health-economics evidence. The intersection most CHROs have not named yet: you do not have three problems, you have one.

The vocabulary to name the shift in your next GMT.
Inside the Briefing · Chapter 2

Four moves across talent, L&D, succession, and trust

Publish the memo the CEO co-signs in your first 100 days. Ship one role redesigned as a triad on live submissions, senior reviewer plus regulatory associate plus agent ensemble. Ask your senior RA director, senior clinical affairs lead, and senior biostatistician to author their own redesigns first. Publish three rules by submission stage for what the workforce can do with AI without asking.

One concrete move per sub-function, starting this quarter.
Inside the Briefing · Chapter 3

Five questions for your next GMT

What your three best senior specialists would say privately about whether the firm's AI strategy is being done for them or to them. The role redesigned at task level in the last twelve months. The 2030 bench and which pathways still exist. The deployment fragments you authored versus the ones you decoded after they shipped. The senior specialists asked to author.

Ask these honestly. The disagreements are the signal.